Idorsia brings new sleep treatment home after nods in USA and EU

Swiss biotech firm Idorsia (SIX: IDIA) has won marketing authorization in its home country for a new insomnia med, Quviviq (daridorexant).

The decision follows US Food and Drug Administration approval at the start of the year, and  European authorization in the spring.

While there are a number of treatments on the market for insomnia, the strength of Idorsia’s approach lies in its ability to avoid prolonged effects the day after administration - a factor which hampers the safety profile of rival products.